Condition: Psoriasis · Sponsor: SFA Therapeutics
The purpose of this study is to determine the safety, metabolism and potential effect of drug product SFA-002 on mild moderate and severe chronic plaque psoriasis. Psoriasis is a common chronic skin disorder that affects over 4 million people. There is no cure for psoriasis and treatment is directed at controlling patients' symptoms.
This description comes directly from the study's public registry record.
VP Development · 267-625-4873 · info@sfatherapeutics.com
Always discuss trial participation with your own doctor first.
| NuLine Clinical Trial Center | Pompano Beach, Florida, United States | Recruiting |
| Axis Clincals USA/ Red River Research Patners. LLC | Fargo, North Dakota, United States | Recruiting |
| Temple University | Philadelphia, Pennsylvania, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05642182